All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNC210
Therapeutic Area: Psychiatry/Psychology Product Name: BNC210
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
Details:
BNC210 novel oral tablet formulation (900 mg given twice daily) exceeds blood exposure projected for upcoming Phase 2b PTSD trial.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNC210
Therapeutic Area: Psychiatry/Psychology Product Name: BNC210
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Apeiron Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing February 10, 2021
Details:
Under the Subscription Agreement dated 2 June 2020 with Apeiron, Apeiron agreed to recapitalise the Company and assist in securing further equity capital to fund the Company's BNC210 Phase 2b Clinical trial for the treatment of post-traumatic stress disorder.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNC210
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Apeiron Investment Group
Deal Size: $22.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 02, 2020
Details:
The financing guarantees the Company's substantiated funding to advance Phase 2 clinical trials for the treatment of PTSD and other anxiety and stress-related disorders for its lead compound, BNC210.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
